Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 15.7 kDa and 30.3 kDa. The protein migrates as 19 kDa,48-53 kDa and 65-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 25 mM MES,150 mM NaCl,pH6.0 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus Coagulation factor X, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Cynomolgus Coagulation factor X, His Tag (Cat. No. F10-C52H9) is more than 90% and the molecular weight of this protein is around 52-70 kDa verified by SEC-MALS.
Price(USD) : $400.00
Price(USD) : $1500.00
Price(USD) : $5600.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rurioctocog alfa | BLB-200; rAHF-PFM | Approved | Baxalta Incorporated | 百因止, Advate | United States | Hemophilia A | null | 2003-07-25 | Hemophilia A | Details |
Enoxaparin Sodium | PRY-005; PK-10169; XRP-4563K; M-enoxaparin; RP-54563; RPY-005 | Approved | Sanofi | Klexane, 克赛, Lovenox, Clexane, Enoxamed | United States | Pulmonary Embolism; Venous Thrombosis | Sanofi-Aventis U.S. Llc | 1993-03-29 | Nephrotic Syndrome; Acute Coronary Syndrome; Hypoxia; Liver Diseases; Thromboembolism; Pre-Eclampsia; Coronavirus Infections; Coronary Disease; Fetal Growth Retardation; Venous Thrombosis; Virus Diseases; Lung Neoplasms; Obstetric Labor, Premature; Postoperative Complications; Thrombophilia; Intraoperative Complications; Catheter-Related Infections; Thrombosis; Carcinoma, Non-Small-Cell Lung; Angina, Unstable; Ovarian Neoplasms; Myocardial Ischemia; ST Elevation Myocardial Infarction; Myocardial Infarction; Venous Thromboembolism; Abdominal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Pain; Pulmonary Embolism; Brain Injuries, Traumatic; Hip Fractures; Coronavirus Disease 2019 (COVID-19); Obesity, Morbid; Pancreatic Neoplasms; Kidney Diseases; Colonic Neoplasms; Neoplasms | Details |
Enoxaparin sodium biosimilar (Gland Pharma) | Approved | Gland Pharma Ltd | Cutenox | Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Venous Thrombosis | Gland Pharma | 2014-10-01 | Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Venous Thrombosis | Details | ||
Human coagulation factor Ⅷ (Chengdu Rongsheng Pharmaceuticals) | Approved | Chengdu Rongsheng Pharmaceuticals Co Ltd | Mainland China | Hemophilia A | Chengdu Rongsheng Pharmaceuticals Co Ltd | 2001-01-01 | Hemophilia A | Details | ||
Von Willebrand factor/coagulation factor VIII complex (human, Octapharma) | Approved | Octapharma | Eqwilate, Wilnativ, Wilate | Germany | Hemophilia A; von Willebrand Diseases | Octapharma | 2005-01-01 | von Willebrand Diseases; Hemophilia A | Details | |
Human coagulation factor VIII (China Biologic Products) | Approved | Taibang Biotech (Shandong) Co Ltd | Mainland China | Hemophilia A | Taibang Biotech (Shandong) Co Ltd | 2012-06-15 | Hemophilia A; Hemorrhage; Blood Loss, Surgical | Details | ||
Enoxaparin sodium biosimilar (Apotex Pty Ltd) | Approved | Apotex | Australia | Myocardial Ischemia; Angina, Unstable; Venous Thromboembolism; Thrombosis; Venous Thrombosis | Apotex | 2020-02-10 | Myocardial Ischemia; Angina, Unstable; Venous Thromboembolism; Venous Thrombosis; Thrombosis | Details | ||
Anti-inhibitor coagulant complex (Baxalta) | Approved | Baxalta Incorporated | Feiba, Prothromplex TOTAL | United States | Hemophilia A; Hemophilia B | Baxalta Incorporated | 1979-12-21 | Blood Coagulation Disorders; Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B; Cardiovascular Diseases | Details | |
Apixaban | BMS-562247-01; BMS-562247; TAH-3311 | Approved | Bristol-Myers Squibb Company | Eliquis, 艾乐妥, 艾乐通 | EU | Venous Thromboembolism | Bristol-Myers Squibb/Pfizer Eeig | 2011-05-18 | Lymphoma; Glomerulonephritis, Membranous; Atrial Fibrillation; Ischemic Attack, Transient; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Genital Neoplasms, Female; Cardiovascular Diseases; Astrocytoma; Colitis, Ulcerative; Primary Myelofibrosis; Aortic Valve Insufficiency; Venous Thrombosis; Hemorrhage; Aortic Valve Stenosis; Thrombocytopenia; Nephrotic Syndrome; Renal Insufficiency, Chronic; Thrombosis; Kidney Failure, Chronic; Anemia, Sickle Cell; Fasting; Rectal Diseases; Crohn Disease; Thrombocythemia, Essential; Inflammatory Bowel Diseases; Bone Marrow Neoplasms; Hematologic Neoplasms; Solid tumours; Rejection of renal transplantation; Embolism; Venous Thromboembolism; Foramen Ovale, Patent; Cerebral Hemorrhage; Death; Polycythemia Vera; Spinal Cord Injuries; Pulmonary Embolism; Neoplasms; Coronavirus Disease 2019 (COVID-19); Proteinuria; Atrial Flutter; Pancreatic Neoplasms; Myeloproliferative Disorders; Glioblastoma; Aortic valve diseases; Acute Coronary Syndrome; Stroke; Thromboembolism | Details |
Turoctocog alfa | NNC0155-0000-0004; NN-7008 | Approved | Novo Nordisk A/S | Zonovate, Novoeight | United States | Hemophilia A | null | 2013-10-15 | Hemophilia A; Hemorrhage | Details |
Human prothrombin complex (Nanyue Biopharming) | Approved | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | 2019-09-05 | Hemophilia B; Hemorrhage | Details | ||
Human Antithrombin III (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | India | Antithrombin III Deficiency | Hemarus Therapeutics | 2015-08-01 | Antithrombin III Deficiency | Details | ||
Enoxaparin sodium biosimilar (Techdow) | Approved | Shenzhen Techdow Pharmaceutical Co Ltd | Inhixa | Mainland China | Embolism and Thrombosis | Shenzhen Techdow Pharmaceutical Co Ltd | 2005-08-18 | Blood Coagulation Disorders; Pulmonary Embolism; Angina, Unstable; Venous Thromboembolism; Coronavirus Disease 2019 (COVID-19); Embolism and Thrombosis; Pneumonia, Viral; Coronavirus Infections; Venous Thrombosis; Non-ST Elevated Myocardial Infarction | Details | |
Moroctocog alfa | PF-05208756; r-VIII SQ; PF-5208756; r-Factor VIII SQ; BDDrFVIII | Approved | Pfizer Inc | ReFacto, Xyntha, Refacto AF, Xyntha Solofuse, Refacto AF/Xyntha, 任捷 | EU | Hemophilia A | Pfizer Europe Ma Eeig | 1999-04-13 | Hemophilia A | Details |
Heparin sodium biosimilar (Chandra Bhagat Pharma) | Approved | Chandra Bhagat Pharma(Cbc) | Thromboparin | India | Thrombosis | Chandra Bhagat Pharma(Cbc) | 2012-08-01 | Thrombosis | Details | |
Factor VIII (Tonrol Biopharmaceuticals) | Hemorass | Approved | Tonrol Bio-Pharmaceutical Co Ltd | HEMORAAS | Hemophilia A | Details | ||||
Danaparoid sodium | KB-101; Org-10172 | Approved | Merck Sharp & Dohme Corp, Organon | Orgaran, Lomoparan | Netherlands | Thrombocytopenia; Venous Thromboembolism | null | 1991-01-01 | Venous Thromboembolism; Thrombocytopenia; Venous Thrombosis | Details |
Eptacog alfa (Novo Nordisk) | NN-007 | Approved | Novo Nordisk A/S | NiaStase, NovoSeven, 诺其 | EU | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Novo Nordisk A/S | 1996-02-23 | Cerebral Hemorrhage; Spinal Diseases; Hemophilia A; Hemophilia B; Fibrosis; Hemorrhage; Stroke; Postpartum Hemorrhage; Factor VII Deficiency; Severe Dengue; Burns; Wounds and Injuries; Blood Loss, Surgical; Thrombasthenia; Acquired hemophilia | Details |
Human prothrombin complex (CSL Behring) | BE-1116 | Approved | Csl Behring Llc | Kcentra, Beriplex, Confidex | Blood Coagulation Disorders; Coagulation Protein Disorders; Heart Failure; Heart Diseases; Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Wounds and Injuries | Details | ||||
Freeze-dried activated human blood coagulation factor Ⅶ concentrate containing factor Ⅹ (Kaketsuken/KM Biologics) | MC-710 | Approved | Kaketsuken | Byclot | Japan | Hemophilia A | null | 2014-07-04 | Hemophilia A | Details |
Trenonacog alfa | IB-1001; APVO-101 | Approved | Inspiration Biopharmaceuticals | Ixinity | United States | Hemophilia B | null | 2015-05-14 | Hemophilia B | Details |
Human prothrombin complex concentrate (Guizhou Taibang Biological Products) | Approved | Guizhou Taibang Biological Products Co Ltd | Mainland China | Hypoprothrombinemias | Guizhou Taibang Biological Products Co Ltd | 2013-07-31 | Hypoprothrombinemias | Details | ||
Enoxaparin sodium biosimilar (PT Kalbe) | Approved | Kalbe Farma | Kalbenox | Cambodia | Angina, Unstable; Myocardial Infarction; Venous Thrombosis | Kalbe Farma | 2012-01-01 | Angina, Unstable; Myocardial Infarction; Venous Thrombosis | Details | |
Rivaroxaban | JNJ-39039039; BAY-59-7939; YHP-1807; YHR-1901 | Approved | Bayer AG, Johnson & Johnson Pharmaceutical Research & Development LLC | Xarelto, 拜瑞妥 | Canada | Atherosclerosis | Bayer AG | 2008-09-15 | Arthritis; Hemorrhage; Embolism and Thrombosis; Atrial Fibrillation; Coronary Disease; Rheumatic Diseases; Rheumatic Heart Disease; Osteoarthritis, Knee; Cardiovascular Diseases; Urologic Neoplasms; Venous Thrombosis; Thrombocytopenia; Antiphospholipid Syndrome; Renal Insufficiency, Chronic; Intraoperative Complications; Obesity; Thrombosis; Respiratory Insufficiency; Osteoarthritis, Hip; Peripheral Arterial Disease; Heart Defects, Congenital; Anemia, Sickle Cell; Kidney Failure, Chronic; Mitral Valve Stenosis; Embolism; Myocardial Ischemia; Upper Extremity Deep Vein Thrombosis; Heart Failure; Venous Thromboembolism; Communicable Diseases; Angina, Unstable; Myocardial Infarction; Atherosclerosis; Diabetes Mellitus, Type 2; Pulmonary Embolism; Coronary Artery Disease; Neoplasms; Kidney Diseases; beta-Thalassemia; Retinal Artery Occlusion; Coronavirus Disease 2019 (COVID-19); Obesity, Morbid; Thromboembolism; Stroke; Acute Coronary Syndrome | Details |
Human Coagulation Factor Ⅷ (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | 康斯平, Kangsiping | Mainland China | Blood Coagulation Disorders; Hemophilia A | Hualan Biological Engineering Inc | 2000-01-01 | Blood Coagulation Disorders; Hemophilia A | Details | |
Antithrombin III (Human, Grifols) | Approved | Grifols Sa | Thrombate III | United States | Thromboembolism; Antithrombin III Deficiency | null | 1991-12-30 | Venous Thromboembolism; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); Thromboembolism; Antithrombin III Deficiency; Postoperative Complications; Wounds and Injuries; Venous Thrombosis | Details | |
Susoctocog alfa | BAX-801; OBI-1; TAK-672; SHP-672; BAX-802 | Approved | Baxalta Incorporated | Obizur | United States | Hemophilia A | null | 2014-10-23 | Hemophilia A; Hemorrhage; Acquired hemophilia | Details |
Enoxaparin sodium biosimilar (Neiss Labs) | Approved | Neiss Labs | Lomonox | India | Venous Thrombosis | Neiss Labs | 2012-08-01 | Venous Thrombosis | Details | |
Certoparin sodium | Approved | Novartis Pharma Ag | Troparin, Alphaparin, Sandoparin, Sandoparine, Mono-Embolex | Pulmonary Embolism; Thromboembolism; Venous Thrombosis | null | 1997-01-01 | Pulmonary Embolism; Embolism; Renal Insufficiency; Thromboembolism; Uremia; Atrial Fibrillation; Venous Thrombosis; Kidney Failure, Chronic | Details | ||
Parnaparin sodium | OP-2123; CB-01-05 | Approved | Opocrin Spa, Alfasigma Spa | Fluxum, Lowhepa, Minidalton | Italy | Thrombosis | null | 1993-01-01 | Thrombophlebitis; Infertility; Thrombosis | Details |
Octocog alfa | BAY14-2222 | Approved | Bayer AG | Kogenate, Helixate NexGen, Kovaltry, Iblias, Kogenate/Kovaltry, 科跃奇 | United States | Hemophilia A | Bayer Healthcare | 1993-02-25 | Blood Coagulation Disorders; Hemophilia A | Details |
Moroctocog alfa biosimilar (International Biotech Center Generium) | GNR-002 | Approved | International Biotech Center Generium | Octofactor | Russian Federation | Hemophilia A | International Biotech Center Generium | 2013-01-01 | Hemophilia A | Details |
Antihemophilic factor/von Willebrand factor (CSL Behring) | Approved | Csl Behring Llc | Aleviate, Biostate, Humate-P, Voncento | United States | von Willebrand Diseases; Hemophilia A | null | 1999-04-01 | von Willebrand Diseases; Hemophilia A | Details | |
Antihemophilic factor B (Armour) | Approved | Csl Behring Llc, Armour Pharma | MonoFIX, Mononine | Hemophilia B | null | 1993-05-01 | Hemophilia B | Details | ||
Ardeparin sodium | Approved | Wyeth-Ayerst | Normiflo | United States | Pulmonary Embolism; Venous Thrombosis | null | 1997-05-01 | Pulmonary Embolism; Venous Thrombosis | Details | |
Dalteparin Sodium | FR-860; KV-165; KABI-2165 | Approved | Pfizer Inc | 法安明, Fragmin | Germany | Thrombosis | Pfizer Inc | 1985-01-01 | Abortion, Habitual; Anemia, Sickle Cell; Thrombosis; Kidney Failure, Chronic; Thrombophilia; Lung Neoplasms; Venous Thrombosis; Colorectal Neoplasms; Pregnancy Complications; Breast Neoplasms; Hepatic Veno-Occlusive Disease; Prostatic Neoplasms; Atrial Fibrillation; Brain Neoplasms; Diabetic Foot; Central Nervous System Neoplasms; Thromboembolism; Puerperal Disorders; Stroke; Coronary Artery Disease; Small Cell Lung Carcinoma; Neoplasms; Brain Injuries, Traumatic; Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Ovarian Neoplasms; Pulmonary Embolism | Details |
Turoctocog alfa pegol | NN-7088; N8-GP; N8-GP-rFVIII; NNC-0129-0000-1003 | Approved | Novo Nordisk A/S | Esperoct | United States | Hemophilia A | Novo Nordisk Inc | 2019-02-19 | Hemophilia A; Hemorrhage | Details |
NecLip-pdFVIII | pdFVIII | Approved | Recoly Nv | LongAte, LongEight | Hemophilia A | Details | ||||
Prothrombinex-VF (CSL Behring) | Approved | Csl Behring Llc | Australia | Hemorrhage | Csl Behring Llc | 2014-10-01 | Hemorrhage | Details | ||
Factor VIII (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemophilia A | Shanxi Kangbao Biological Product Co Ltd | 2020-08-14 | Hemophilia A | Details | ||
Factor VIII biosimilar (Chia Tai-Tianqing) | KN-008 | Approved | Suzhou Alphamab Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 安恒吉 | Mainland China | Hemophilia A | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-08-29 | Hemophilia A | Details |
Recombinant Human Coagulation Factor VIII (sinocelltech) | SCT-800 | Approved | SinoCelltech Ltd | Mainland China | Hemophilia A | SinoCelltech Ltd | 2021-07-20 | Hemophilia A; Blood Loss, Surgical | Details | |
Efmoroctocog alfa | BIIB-031; rFVIIIFc | Approved | Biogen Inc, Sobi, Bioverativ Inc | Elocta, Eloctate | United States | Hemophilia A | null | 2014-06-06 | Hemophilia A | Details |
Efanesoctocog alfa | BIVV-001; BIVV001 | Approved | Amunix Pharmaceuticals Inc | Altuviiio | United States | Hemophilia A | Sanofi | 2023-02-23 | von Willebrand Diseases; Hemophilia A | Details |
Lonoctocog alfa | CSL-627; NBP-601 | Approved | Csl Behring Llc, Sk Chemicals | Afstyla | United States | Hemophilia A | Csl Behring Ag | 2016-05-25 | Hemophilia A | Details |
Antihemophilic Factor (Recombinant) | Approved | Baxalta Incorporated | Recombinate | United States | Hemophilia A | null | 1992-12-10 | Hemophilia A | Details | |
Prothrombin complex concentrate (Sanquin) | Approved | Sanquin Plasma Products Bv | Cofact | Hemorrhage | Sanquin Plasma Products Bv | 2007-11-01 | Hemorrhage | Details | ||
Enoxaparin sodium biosimilar (Rovi) | Approved | Rovi | Arovi | Angina, Unstable; Myocardial Infarction; Venous Thrombosis | Rovi | 2018-03-31 | Angina, Unstable; Myocardial Infarction; Venous Thrombosis | Details | ||
Emicizumab | RG-6013; ACE-910; RO-5534262 | Approved | Genentech Inc, Chugai Pharmaceutical Co Ltd | 舒友立乐, Hemlibra | United States | Hemophilia A | Genentech Inc | 2017-11-16 | Hemophilia A; Hemorrhage; von Willebrand Disease, Type 3 | Details |
Human Coagulation Factor IX (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | Clotnine | India | Hemophilia B | Hemarus Therapeutics | 2015-08-01 | Hemophilia B | Details | |
Factor XP Behring (CSL Behring) | Approved | Csl Behring Llc | Spain | Factor X Deficiency | Csl Behring Llc | 2015-09-01 | Factor X Deficiency | Details | ||
Enoxaparin sodium biosimilar (Blau Pharmaceuticals) | Approved | Blau Pharmaceuticals | Enoxalow | Thrombosis | Blau Pharmaceuticals | 2013-07-01 | Thrombosis | Details | ||
Nonacog alfa | rh-F-IX; rh-Factor-IX | Approved | Pfizer Inc | 贝赋, BeneFIX | EU | Hemophilia B | Pfizer Europe Ma Eeig | 1997-08-27 | Hemophilia B | Details |
Eptacog alfa biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Iran | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Aryogen Biopharma | 2014-01-01 | Hemophilia A; Hemophilia B; Factor VII Deficiency; Thrombasthenia | Details | ||
Nonacog alfa (International Biotech Center Generium) | GNR-003 | Approved | International Biotech Center Generium | Innonafactor | Russian Federation | Hemophilia B | International Biotech Center Generium | 2014-01-01 | Hemophilia B | Details |
Factor IX complex (Grifols) | Approved | Grifols Sa | Profilnine | United States | Hemophilia B | null | 1981-07-21 | Intracranial Hemorrhages; Hemophilia B | Details | |
Edoxaban Tosilate Hydrate | DU-176b | Approved | Daiichi Sankyo Co Ltd | Savaysa, 里先安, Roteas, Lixiana, Lixiana/Savaysa | Japan | Venous Thromboembolism; Venous Thrombosis; Stroke; Embolism; Pulmonary Embolism | Daiichi Sankyo Co Ltd | 2011-04-22 | HIV Infections; Embolism; Pulmonary Embolism; Venous Thromboembolism; Neoplasms; Heart Diseases; Stroke; Thromboembolism; Embolism and Thrombosis; Atrial Fibrillation; Osteoarthritis, Knee; Inflammation; Venous Thrombosis; Obesity; Aortic Valve Stenosis; Thrombosis | Details |
Nonacog beta pegol | N9-GP; NN-7999; 40K-PEG-rFIX; NNC-0156-0000-0009 | Approved | Novo Nordisk A/S | Rebinyn, Refixia | United States | Hemophilia B | Novo Nordisk Inc | 2017-05-31 | Hemophilia B; Hemorrhage | Details |
Human coagulation factor VIII (Green Cross Biological Products) | Approved | GC Biopharma Corp | Mainland China | Blood Coagulation Disorders | Green Cross China Biological Products Co Ltd | 2000-01-01 | Blood Coagulation Disorders | Details | ||
Enoxaparin sodium biosimilar (Harvest Moon Pharmaceuticals) | Approved | Harvest Moon | Angina, Unstable; Myocardial Infarction; Venous Thromboembolism; Venous Thrombosis | Details | ||||||
Eptacog beta | LR-769; rhFVIIa | Approved | Lfb Biotechnologies Sas, Revo Biologics Inc | Sevenfact | United States | Hemophilia A; Hemophilia B | Lfb Biotechnologies Sas | 2020-04-01 | Hemophilia A; Hemophilia B | Details |
Simoctocog alfa | Factor VIII; Human-cl rhFVIII | Approved | Octapharma | Vihuma, Nuwiq | EU | Hemophilia A | Octapharma Ab | 2014-07-22 | Hemophilia A | Details |
Human prothrombin complex (Octapharma) | Approved | Octapharma | Ocplex, Octaplex, Pronativ | Germany | Hemorrhage | Octapharma | 2003-03-14 | Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Nonacog gamma | rFIX; BAX-326 | Approved | Baxalta Incorporated | Rixubis | United States | Hemophilia B | null | 2013-06-26 | Hemophilia B | Details |
Factor VIII/von Willebrand factor (Bio Products Laboratory) | Approved | Bio Products Laboratory Ltd | Optivate | Hemophilia A | Bio Products Laboratory Ltd | 2004-12-01 | von Willebrand Diseases; Hemophilia A | Details | ||
Eptacog alfa biosimilar (International Biotech Center Generium) | GNR-001 | Approved | International Biotech Center Generium | Russian Federation | Hemophilia A | International Biotech Center Generium | 2015-01-01 | Hemophilia A | Details | |
Antihemophilic factor/von Willebrand factor complex (Human, Grifols Biologicals) | Approved | Grifols Sa | Alphanate | United States | Hemophilia A; von Willebrand Diseases | null | 1978-08-15 | von Willebrand Diseases; Hemophilia A | Details | |
Rurioctocog alfa pegol | BAX-0855; BAX-855; TAK-660 | Approved | Baxalta Incorporated, Nektar Therapeutics | Adynovi, Adynovate | United States | Hemophilia A | null | 2015-11-13 | Hemophilia A | Details |
Human prothrombin complex (LFB) | Approved | Lfb Biotechnologies Sas | KANOKAD | France | Hemorrhage | Lfb Biotechnologies Sas | 2008-09-01 | Hemorrhage | Details | |
Eftrenonacog Alfa | BIIB-029; FIX:Fc; FIXFc; rFIXFc | Approved | Sobi, Biogen Inc, Bioverativ Inc | Alprolix, 赛玖凝 | United States | Hemophilia B | null | 2014-03-28 | Hemophilia B | Details |
Factor VIII (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Factocel VIII | Hemophilia A | Details | |||||
Moroctocog alfa biosimilar (Amega Biotech) | Approved | Amega Biotech | Argentina | Hemophilia A | Amega Biotech | 2012-01-01 | Hemophilia A | Details | ||
Fondaparinux Sodium | GSK-576428; Org-31540; SR-90107; SR-90107A | Approved | Organon | Arixtra, Quixidar, 安卓 | United States | Liver Diseases; Pulmonary Embolism; Venous Thrombosis | Mylan Ireland Ltd | 2001-12-07 | Liver Diseases; Uterine Cervical Neoplasms; Endometrial Neoplasms; Venous Thrombosis; Fallopian Tube Neoplasms; Atrial Fibrillation; Vulvar Neoplasms; Sarcoma; Coronary Disease; Angina Pectoris; Pulmonary Embolism; Thromboembolism; Neoplasms; Obesity, Morbid; Renal Insufficiency; Vaginal Neoplasms; Venous Thromboembolism; Angina, Unstable; Myocardial Infarction; Ovarian Neoplasms | Details |
Enoxaparin sodium biosimilar (Chandra Bhagat Pharma) | Approved | Chandra Bhagat Pharma(Cbc) | MAXIPARINE | Venous Thrombosis | Details | |||||
Antithrombin III (CSL Behring) | BI51.017 | Approved | Csl Behring Llc | Kybernin, Anthrobin, Athimbin | Japan | Thrombosis; Disseminated Intravascular Coagulation | Csl Behring Llc | 1987-08-02 | Disseminated Intravascular Coagulation; Thrombosis | Details |
Heparin sodium biosimilar (Blau Pharmaceuticals) | Approved | Blau Pharmaceuticals | Hepamax-S | Brazil | Thrombosis | Blau Pharmaceuticals | 2012-08-01 | Thrombosis | Details | |
Human prothrombin complex (Tonrol Biopharmaceuticals) | Approved | Tonrol Bio-Pharmaceutical Co Ltd | ProthoRAAS | Mainland China | Hemorrhage | Shanghai Raas Blood Products Co Ltd | 1996-01-01 | Hemophilia B; Hemorrhage | Details | |
Human Coagulation Factor VIII (Hemarus Therapeutics) | Approved | Hemarus Therapeutics | CLOTATE | India | Hemophilia A | Hemarus Therapeutics | 2015-08-01 | Hemophilia A | Details | |
Human factor IX (LFB) | Approved | Lfb Biotechnologies Sas | Betafact | Netherlands | Hemophilia B | Lfb Biotechnologies Sas | 2000-05-01 | Hemophilia B | Details | |
Albutrepenonacog alfa | CSL-640; CSL-654 | Approved | Csl Behring Llc | Idelvion | United States | Hemophilia B | null | 2016-03-04 | Hemophilia B | Details |
Enoxaparin sodium biosimilar (Fresenius Kabi) | Approved | Fresenius Kabi Canada Ltd | ELONOX, ELONOX HP | Canada | Thromboembolism; Venous Thrombosis | Fresenius Kabi Canada Ltd | 2022-10-26 | Thromboembolism; Venous Thrombosis | Details | |
Recombinant Human Coagulation Factor Ⅷ (Chengdu Rongsheng Pharmaceuticals) | Approved | Chengdu Rongsheng Pharmaceuticals Co Ltd | Mainland China | Hemophilia A | Chengdu Rongsheng Pharmaceuticals Co Ltd | 2023-09-05 | Hemophilia A | Details | ||
Human prothrombin complex (Guangdong Shuanglin) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia B | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2023-05-12 | Hemophilia B | Details | ||
Human coagulation factor Ⅷ (Shanghai Xinxing) | Approved | Shanghai Xinxing Medicine Co Ltd | Mainland China | Hemophilia A; Hemorrhagic Disorders | Shanghai Xinxing Medicine Co Ltd | 2015-07-27 | Hemorrhagic Disorders; Hemophilia A | Details | ||
Human coagulation factor Ⅷ (Shanghai Institute of Biological Products) | Approved | Shanghai Institute Of Biological Products Co Ltd | Mainland China | Hemophilia A; Hemorrhagic Disorders | Shanghai Institute Of Biological Products Co Ltd | 2012-07-23 | Hemorrhagic Disorders; Hemophilia A | Details | ||
Human coagulation factor Ⅷ (Shandong Taibang) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Shandong Taibang Biological Products Co Ltd | 2012-06-15 | Details | ||||
Human Coagulation Factor Ⅷ (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemophilia A | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 2012-07-23 | Hemophilia A | Details | ||
Human prothrombin complex (Shanghai Xinxing) | Approved | Shanghai Xinxing Medicine Co Ltd | Mainland China | Hemorrhage | Shanghai Xinxing Medicine Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
Human prothrombin complex (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemorrhage | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
Human prothrombin complex (Boya Bio-Pharmaceutical) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemorrhage | Boya Bio-Pharmaceutical Group Co Ltd | 2020-12-02 | Hemophilia B; Hemorrhage | Details | ||
Human prothrombin complex (Guangdong Wellen) | Approved | Guangdong Wellen Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Guangdong Wellen Pharmaceutical Co Ltd | 2020-10-21 | Hemophilia B; Hemorrhage | Details | ||
Human Coagulation Factor Ⅷ (Shanghai Raas Blood Products) | Approved | Shanghai Raas Blood Products Co Ltd | Mainland China | Hemophilia A | Shanghai Raas Blood Products Co Ltd | 1995-01-01 | Hemophilia A | Details | ||
Factor IX (Bio Products Laboratory) | Approved | Bio Products Laboratory Ltd | Replenine-VF | United Kingdom | Hemophilia B | Bio Products Laboratory Ltd | 1999-08-09 | Hemophilia B | Details | |
Human Coagulation Factor Ⅷ(Tonrol Bio-Pharmaceutical ) | Approved | Tonrol Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia A | Tonrol Bio-Pharmaceutical Co Ltd | 2013-08-23 | Hemophilia A | Details | ||
Antithrombin III (Octapharma Ab) | Approved | Octapharma Ab | Atenativ | EU | Antithrombin III Deficiency | Octapharma Ab | 2007-12-20 | Antithrombin III Deficiency | Details | |
Human prothrombin complex(Hebei Daan Pharmaceutical) | Approved | Hebei Daan Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hebei Daan Pharmaceutical Co Ltd | 2020-01-01 | Hemophilia B; Hemorrhage | Details | ||
Human Coagulation Factor Ⅷ (Jiangxi Boya Bio-Pharmaceutical ) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemophilia A | Boya Bio-Pharmaceutical Group Co Ltd | 2022-08-08 | Hemophilia A; Hemorrhage | Details | ||
Human Coagulation Factor Ⅷ (Guangdong Shuanglin Bio-Pharmaceutical) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia A | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2020-06-17 | Hemophilia A | Details | ||
Human coagulation factor Ⅷ (Shenzhen Weiguang Biological Products) | Approved | Shenzhen Weiguang Biological Products Co Ltd | Mainland China | Hemophilia A | Shenzhen Weiguang Biological Products Co Ltd | 2023-10-27 | Hemophilia A | Details | ||
Polysulfonic mucopolysaccharide | M-118102; M-1180B; M-7040B | Approved | Maruho Co Ltd | 喜辽妥, 喜疗妥 | Japan | Chilblains; Cicatrix; Arthritis; Thrombophlebitis | Maruho Co Ltd | 1954-10-01 | Phlebitis; Thrombophlebitis; Chilblains; Contusions; Cicatrix; Arthritis | Details |
Human coagulation factor VIII(Biotest Pharma Gmbh) | Approved | Biotest Pharma Gmbh | Haemoctin SDH | Hemophilia A | Details | |||||
Human Coagulation Factor IX(China Biologic Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemophilia B | Shandong Taibang Biological Products Co Ltd | 2020-07-08 | Hemophilia B | Details | ||
Factor IX (Sichuan Yuanda Shuyang Pharmaceutical) | Approved | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | Mainland China | Hemophilia B | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | 2023-02-14 | Hemophilia B; Hemorrhage | Details | ||
Prothrombin complex concentrat (Taibang Biological Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemorrhage | Shandong Taibang Biological Products Co Ltd | 2014-09-30 | Hemorrhage; Antithrombin III Deficiency | Details | ||
Human prothrombin complex (Hualan Biological Engineering) | Approved | Hualan Genetic Engineering Co Ltd | Mainland China | Blood Coagulation Disorders; Factor X Deficiency | Hualan Biological Engineering Inc | 1999-01-01 | Blood Coagulation Disorders; Hemophilia B; Factor X Deficiency | Details | ||
Enoxaparin sodium biosimilar (Sahar International Trading) | Approved | Sahar International Trading | Angina, Unstable; ST Elevation Myocardial Infarction; Venous Thromboembolism; Blood Coagulation Disorders | Sahar International Trading | 2013-07-01 | Blood Coagulation Disorders; Angina, Unstable; ST Elevation Myocardial Infarction; Venous Thromboembolism | Details | |||
Human prothrombin complex concentrate (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemorrhage | Shanxi Kangbao Biological Product Co Ltd | 2019-09-17 | Hemophilia B; Hemorrhage | Details | ||
Beroctocog alfa | GC-1101; GC-1101C | Approved | GC Biopharma Corp | GreenGene F | South Korea | Hemophilia A | GC Biopharma Corp | 2009-12-01 | Hemophilia A | Details |
Damoctocog alfa pegol | BAY-949027 | Approved | Bayer AG | Jivi | United States | Hemophilia A | Bayer Healthcare | 2018-08-29 | Hemophilia A; Hemorrhage | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Factor VIII (CSL/Zhong Yuan Rui De Biological Products) | Phase 3 Clinical | Csl Ltd | Hemophilia A | Details | |
Mim8 | Mim8; NN7769; NNC0365-3769; NN-7769 | Phase 3 Clinical | Novo Nordisk A/S | Hemophilia A | Details |
Recombinant factor VIII (Saman daroo 8) | Phase 3 Clinical | Saman Daroo 8 | Hemophilia A | Details | |
Human coagulation factor VIII (Jiangxi Boya Bio-pharmaceutical) | Phase 3 Clinical | Boya Bio-Pharmaceutical Group Co Ltd | Hemophilia A | Details | |
PEG-Recombinant FVIII-Fc fusion protein (Furen Medicines) | FRSW-117 | Phase 3 Clinical | Kaifeng Pharmaceutical (Group) Co Ltd | Blood Coagulation Disorders; Hemophilia A | Details |
Eptacog Alfa Biosimilar(Aryogen Pharmed) | Phase 3 Clinical | Aryogen Pharmed Co | Hemophilia A; Factor VII Deficiency | Details | |
Factor IX (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Biological Engineering Inc | Hemophilia B | Details | |
Factor IX (Guangdong Shuanglin Bio-Pharmaceutical) | Phase 3 Clinical | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Hemophilia B | Details | |
CT-001 (Coagulant Therapeutics) | CT-001; CT001 | Phase 3 Clinical | Coagulant Therapeutics Corp | Pain; Postpartum Hemorrhage | Details |
Ketamine/sufentanil nasal spray (Cessatech) | CT-001 (Cessatech); CT-001 | Phase 3 Clinical | Cessatech A/S | Pain; Anesthesia; Hemorrhage | Details |
Recombinant Human Coagulation Factor Ⅷ (Zhuangya Biotechnology) | Phase 3 Clinical | Zhuangya (Beijing) Biotechnology Co Ltd | Hemophilia A | Details | |
Human prothrombin complex concentrate (Sichuan Yuanda Shuyang Pharmaceutical) | Phase 3 Clinical | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | Blood Coagulation Disorders | Details | |
Dimolegin | DD-217 | Phase 3 Clinical | Pharmadiall Ltd | Venous Thromboembolism; Coronavirus Disease 2019 (COVID-19) | Details |
Human coagulation factor Ⅷ /Human von Willebrand factor (Shandong Taibang Biological Products) | Phase 3 Clinical | Shandong Taibang Biological Products Co Ltd | von Willebrand Diseases; von Willebrand Disease, Type 1; Hemophilia A; Acquired hemophilia | Details | |
Coagulation factor VIII (Hebei Daan Pharma) | Phase 3 Clinical | Hebei Daan Pharmaceutical Co Ltd | Hemophilia A | Details | |
Human prothrombin complex concentrate (Harbin Shiheng Bioengineering Pharmaceutical) | Phase 3 Clinical | Harbin Pacific Biopharmaceutical Co Ltd | Hemophilia B | Details | |
Human prothrombin complex (Lanzhou Lansheng Blood Products) | Phase 3 Clinical | Lanzhou Lansheng Blood Products Co Ltd | Hemophilia B | Details | |
Recombinant human coagulation factor VIIa (Chengdu Rongsheng Pharmaceuticals) | Phase 3 Clinical | Chengdu Rongsheng Pharmaceuticals Co Ltd | Hemophilia A | Details | |
Human prothrombin complex(Hunan Ziguang Huhan Nanyue Pharmaceutical) | Phase 3 Clinical | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Hemophilia B | Details | |
aPCC-emicizumab | Phase 3 Clinical | Emory University | Hemophilia A | Details | |
Human coagulation factor Ⅷ (Chengdu Institute Of Biological Products) | Phase 3 Clinical | Chengdu Institute Of Biological Products Co Ltd | Hemophilia A | Details | |
Ciraparantag | PER-977 | Phase 2 Clinical | Perosphere Inc | Hemorrhagic Disorders | Details |
Zifaxaban | TY-602 | Phase 2 Clinical | Tianjin Remedy Research Institute | Pulmonary Embolism; Venous Thrombosis | Details |
Coagulation factor X activators (Staidson) | STSP-0601 | Phase 2 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Hemorrhagic Disorders; Hemophilia A; Hemophilia B; Hemorrhage; Blood Loss, Surgical | Details |
Factor VIIa-CTP | MOD-5014; MOD-5017; OPK88005 | Phase 2 Clinical | Opko Health Inc, Prolor Biotech | Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B | Details |
Tearexaban | TRx1 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Stroke; Venous Thrombosis | Details |
Recombinant human coagulation factor VIIa-Fc fusion protein(Jiangsu Gensciences) | SS109; SS-109 | Phase 2 Clinical | Jiangsu Gensciences lnc | Hemophilia A; Hemophilia B; Factor VII Deficiency | Details |
NXT-007 | NXT-007; RG-6512; RO-7589655 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Hemophilia A | Details |
Pegylated Liposome Simoctocog Alfa | PEGLip | Phase 2 Clinical | Ascension Healthcare Development Ltd | Hemophilia A | Details |
R-1663 | R-1663 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Thrombosis | Details |
SAR-107375-E | SAR-107375-E; SAR-107375E | Phase 1 Clinical | Sanofi | Venous Thrombosis | Details |
Eptacog alfa biosimilar (Valin Technologies) | Phase 1 Clinical | Valin Technologies | Hemophilia A | Details | |
Marzeptacog alfa | CB-813; CB-813d; PF-5280602; PF-05280602 | Phase 1 Clinical | Catalyst | Hemophilia A; Hemophilia B | Details |
CX-3002 | CX-3002 | Phase 1 Clinical | Chengdu Easton Biopharmaceuticals Co Ltd | Venous Thrombosis | Details |
Renaparin | Phase 1 Clinical | Vedanta Biosciences Inc | Delayed Graft Function | Details | |
WA1-089 | WA1-089 | Phase 1 Clinical | North China Pharmaceutical Company Ltd | Venous Thromboembolism | Details |
SYHA136 | SYHA-136 | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Venous Thromboembolism; Venous Thrombosis | Details |
Human prothrombin complex (National Drug Group Wuhan Blood) | Phase 1 Clinical | National Drug Group Wuhan Blood Products Co Ltd | Hemorrhage | Details | |
Rivaroxaban (Bio-synectics) | BS-112 | Phase 1 Clinical | Bio-Synectics Inc | Pulmonary Embolism; Venous Thrombosis | Details |
Rivaroxaban (Austhera Biosciences) | AST-8294; DST-8294; KRIVA | Phase 1 Clinical | Dispersol Technologies Llc | Antiphospholipid Syndrome | Details |
Human coagulation factor Ⅷ (Guizhou Taibang Biological Products) | Phase 1 Clinical | Guizhou Taibang Biological Products Co Ltd | Details | ||
CKD-344 | CKD344; CKD-344 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Details | |
Noxaban | Phase 1 Clinical | Zhaoke Pharmaceutical (Guangzhou) Co Ltd | Venous Thromboembolism; Liver Cirrhosis | Details | |
HR-17020 | HR17020; HR-17020 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Venous Thromboembolism; Thromboembolism; Nephrotic Syndrome | Details |
GS001 | GS-001 | Clinical | Institute Of Hematology & Blood Diseases Hospital | Hemophilia A | Details |
This web search service is supported by Google Inc.